WHAN IN PHARM CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13,830 KRW | -0.29% |
|
+1.77% | -8.05% |
| 2023 | Whan In Pharm Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
| 2015 | Whanin Pharmaceutical Co. Ltd.(KOSE:A016580) added to Russell Global Index | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 235,876 | 254,960 | 271,754 | 268,700 | 229,617 | 211,144 | - |
| Enterprise Value (EV) 2 | 235.9 | 207.5 | 186.4 | 219.3 | 229.6 | 176.1 | 167.8 |
| P/E ratio | 12.6 x | 10.9 x | 10.3 x | 11.2 x | 7.71 x | 9.2 x | 8.46 x |
| Yield | - | 1.8% | 1.69% | 1.7% | - | 2.17% | 2.17% |
| Capitalization / Revenue | - | 1.48 x | 1.53 x | 1.35 x | 1 x | 0.85 x | 0.78 x |
| EV / Revenue | - | 1.21 x | 1.05 x | 1.1 x | 1 x | 0.71 x | 0.62 x |
| EV / EBITDA | - | 6.61 x | 4.98 x | 6.37 x | 6.23 x | 4.32 x | 3.77 x |
| EV / FCF | - | - | 5,762,411 x | -4,363,269 x | - | - | - |
| FCF Yield | - | - | 0% | -0% | - | - | - |
| Price to Book | - | 0.86 x | 0.86 x | 0.81 x | - | 0.68 x | 0.64 x |
| Nbr of stocks (in thousands) | 15,267 | 15,267 | 15,267 | 15,267 | 15,267 | 15,267 | - |
| Reference price 3 | 15,450 | 16,700 | 17,800 | 17,600 | 15,040 | 13,830 | 13,830 |
| Announcement Date | 3/12/20 | 2/8/21 | 2/9/22 | 2/13/23 | 2/14/24 | - | - |
1KRW in Million2KRW in Billions3KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 171.7 | 177.8 | 198.9 | 230.4 | 248.8 | 271.3 |
| EBITDA 1 | - | 31.41 | 37.43 | 34.42 | 36.83 | 40.8 | 44.5 |
| EBIT 1 | - | 28.42 | 31.28 | 29.81 | 30.17 | 31.9 | 35.5 |
| Operating Margin | - | 16.55% | 17.59% | 14.98% | 13.09% | 12.82% | 13.09% |
| Earnings before Tax (EBT) 1 | - | 31.08 | 33.88 | 29.81 | 33.79 | 34.8 | 38.4 |
| Net income 1 | 0.0187 | 23.39 | 26.66 | 23.92 | 29.77 | 28 | 30.4 |
| Net margin | - | 13.62% | 15% | 12.02% | 12.92% | 11.25% | 11.21% |
| EPS 2 | 1,225 | 1,532 | 1,726 | 1,567 | 1,950 | 1,503 | 1,634 |
| Free Cash Flow | - | - | 32,350 | -50,265 | - | - | - |
| FCF margin | - | - | 18,197.21% | -25,267.1% | - | - | - |
| FCF Conversion (EBITDA) | - | - | 86,430.42% | - | - | - | - |
| FCF Conversion (Net income) | - | - | 121,348.42% | - | - | - | - |
| Dividend per Share 2 | - | 300.0 | 300.0 | 300.0 | - | 300.0 | 300.0 |
| Announcement Date | 3/12/20 | 2/8/21 | 2/9/22 | 2/13/23 | 2/14/24 | - | - |
1KRW in Billions2KRW
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 44.97 | 44.99 | 48.84 | 48.57 | 49.36 | 52.16 | 55.54 | 57.63 | 58.84 |
| EBITDA | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 7.283 | 4.305 | 9.716 | 6.422 | 7.137 | 6.266 | 7.39 | 8.544 | 7.785 |
| Operating Margin | 16.19% | 9.57% | 19.89% | 13.22% | 14.46% | 12.01% | 13.31% | 14.83% | 13.23% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/1/21 | 2/9/22 | 4/28/22 | 7/29/22 | 10/28/22 | 2/13/23 | 4/28/23 | 7/28/23 | 10/31/23 |
1KRW in Billions
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 47.5 | 85.3 | 49.4 | - | 35 | 43.3 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | 32,350 | -50,265 | - | - | - |
| ROE (net income / shareholders' equity) | - | 8.21% | 8.59% | 7.36% | - | 7.6% | 7.8% |
| ROA (Net income/ Total Assets) | - | 7.37% | 7.72% | 6.62% | - | 6.9% | 7% |
| Assets 1 | - | 317.2 | 345.1 | 361.3 | - | 405.8 | 434.3 |
| Book Value Per Share 2 | - | 19,396 | 20,761 | 21,845 | - | 20,338 | 21,725 |
| Cash Flow per Share 2 | - | 1,490 | 2,429 | 1,104 | - | 1,808 | 1,915 |
| Capex 1 | - | 7.99 | 4.73 | 67.1 | - | 10.6 | 10.7 |
| Capex / Sales | - | 4.65% | 2.66% | 33.74% | - | 4.26% | 3.94% |
| Announcement Date | 3/12/20 | 2/8/21 | 2/9/22 | 2/13/23 | 2/14/24 | - | - |
1KRW in Billions2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
13,830
KRW
Average target price
21,000
KRW
Spread / Average Target
+51.84%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -8.05% | 153M | |
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- A016580 Stock
- Financials Whan In Pharm Co.,Ltd.
